Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Exclusive Article Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?Reported by Jennifer Woods. Date Posted: 3/2/2026. After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has rallied to a price it hasn't seen in nearly four years. The stock has surged almost 260% over the past year, including a 58% jump in the last month alone. The rally has been driven by strong earnings and a wave of bullish analyst commentary. Yet the consensus 12-month price target sits at just $12.25 — nearly 30% below the current share price. That raises a key question: how much of FIGS' recovery is supported by fundamentals, and how much is momentum? A closer look at recent results and the stock's price action offers some clues. Early investors in FIGS saw a quick windfall after the company's May 2021 IPO, which priced at $22 and climbed to about $50 per share within a month as demand for medical apparel surged during the COVID-19 pandemic. As the pandemic eased, shares reversed sharply and were trading below $8 within a year. In the years that followed, FIGS largely traded in the single digits. After dipping under $4 in April 2025, the stock began another upward move — this time sustained. Earnings Momentum Sparks Rally After steady gains following positive Q1 and Q2 2025 earnings reports, the Q3 2025 results, released on Nov. 6, pushed the stock higher. The report showed stronger-than-expected revenue growth, solid demand across FIGS' core business and healthy margins despite tariff-related headwinds. The company also raised full-year guidance for net revenue and adjusted EBITDA margins. Wall Street responded, sending the stock up more than 30% over the following week and prompting Zacks Research to upgrade the stock to Strong Buy from Hold. I Called Black Monday. Now I'm Calling March 26!
I predicted the 1987 crash six weeks early. I called the fall of the Berlin Wall. I pinpointed the exact bottom in 2009.
Now I'm staking my reputation on March 26, 2026 - the day I believe Elon will announce the SpaceX IPO.
Bloomberg is calling it "the biggest listing of ALL TIME."
A $1.5 TRILLION valuation... the "wealth-building" moment of the decade.
Today, I'll show you how to get in before the big announcement. Click Here to See How to Secure Your "SpaceX Access Code" Key Points - FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
The rally continued after the release of the Q4 2025 earnings report on Feb. 26. The quarter featured a 33% increase in revenue and marked the company's best quarterly sales, with revenue topping $200 million. In the earnings call, FIGS highlighted strength across the business, including growth in its active customer base and higher average order values. The company also noted the visibility boost from outfitting Team USA's medical staff at the Winter Olympics. Scrubwear — which accounted for more than three-quarters of net revenue — was a particular bright spot, rising 35%, while international sales jumped 55%. The fourth quarter capped a strong year: full-year net revenue rose 14% to a record $630 million, and full-year adjusted EBITDA margin beat targets by over 200 basis points despite tariff pressure on gross margins. Earnings And Outlook Spark Analyst Support FIGS issued an upbeat outlook for the year ahead, forecasting continued demand supported in part by growth in healthcare employment. Management outlined plans to expand into new international markets, prioritize growth opportunities across businesses and continue its share buyback program. For fiscal 2026, FIGS expects net revenue to grow 10% to 12% with improving profitability. Analysts followed with a flurry of positive updates. Barclays upgraded to Strong Buy from Hold, KeyCorp moved to Overweight from Sector Weight with a $17 price target, and Goldman Sachs shifted to Hold from Strong Sell. BTIG reiterated a Buy rating with a $15 target, and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets Strong results have been the primary catalyst behind FIGS' move to four-year highs. Shares began climbing ahead of the Q4 report, jumping nearly 14% in the session before the release, and the rally accelerated afterward. The stock surged 24% on the first trading day following the report and gained another 10% the next day. As of March 4, the stock was trading above $17 — almost 30% above the average 12-month price target of $12.25 based on 10 analyst reports. That level is more than double Morgan Stanley's $8 target issued in January and sits at or above most other analyst targets, including the $17 set by KeyCorp. The gap between bullish analyst commentary and relatively modest price targets suggests analysts appreciate FIGS' improving fundamentals but remain cautious about valuation. At the current price, shares trade at a price-to-earnings ratio approaching 90, implying much of FIGS' expected growth may already be priced in. Investors have rewarded the company's turnaround, but questions remain about whether the rally can continue or if a pullback could be coming.
| 
